Depression Drugs Market: Competitive Landscape Analysis with Forecast by 2030

According to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030.

Depression Drugs Market: Introduction

According to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030. Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression. Various drug classes are used to treat depression. These include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, and tricyclic antidepressants. Rise in prevalence of depression and increase in incidence of depression among the geriatric population is boosting the global depression drugs.

North America dominated the global depression drugs market in 2019. This trend is anticipated to continue during the forecast period. Growth in awareness about the availability of new drugs to treat depression and presence of major companies in the region are expected to drive the depression drugs market in North America. Asia Pacific is likely to be a highly lucrative region of the global depression drugs market during the forecast period.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1151

Rise in Prevalence of Depression and Increase in Geriatric Population to Drive Market

MDD is a commonly diagnosed form of depression. In 2015, around 16.1 million adults aged 18 years and above in the U.S. experienced at least one major depression episode. This represented 6.7% of all adults in the country. Depression is the leading cause of disability among people aged between 15 and 44 in the U.S. More than 41,000 suicides are committed every year in the U.S. Depression is one of the most common illnesses among the elderly population.

In addition to the common risk factors prevalent among all age groups, chronic diseases, restricted mobility, bereavement, abuse, isolation, and loss of income are the major risk factors for depression among the geriatric population. The prevalence of depression among adults aged 65 and older is estimated to be between 5% and 10%. Depression is projected to be the second leading cause of disease burden in this age group by 2020.

Request for Analysis of COVID19 Impact on Dry Eye Disease Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1151

Atypical Antidepressants Drug Class to Dominate Market

Based on drug class, the global depression drugs market has been divided into Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, tricyclic antidepressants, and others. The atypical antidepressants segment dominated the global depression drugs market in 2019. This trend is projected to continue during the forecast period, as it is first-line of treatment, and due to increase in cases of depression and launch of new drugs.

Schizophrenia and Bipolar I Disorder to be Promising Disease Type

In terms of disease type, the global depression drugs market has been classified into Major Depressive Disorder (MDD), schizophrenia and  bipolar I disorder, Obsessive-Compulsive Disorders (OCD), anxiety disorder, and others. The schizophrenia and  bipolar I disorder segment is expected to expand at the highest CAGR during the forecast period. Rise in cases of schizophrenia and bipolar I disorder and increase in research on the treatment of this disorder are driving the segment. The World Health Organization considers bipolar disorder to be the sixth-largest cause of disability across the globe. According to the WHO data published in October 2019, 20 million people across the globe have been affected with schizophrenia.

Retail Pharmacies Segment Accounted for Major Share of Global Market

Based on distribution channel, the global depression drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment led the global depression drugs market in terms of revenue in 2019. This trend is anticipated to continue during the forecast period. Increase in number of depression drugs being dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries make these a major channel of distribution.

Buy Depression Drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=1151&ltype=S

North America to Lead Global Market

The global depression drugs market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global depression drugs market in 2019. It was followed by Europe. The introduction of new drugs to treat depression and high prevalence of mental illness in developed countries such as the U.S. drive the depression drugs market in North America. The depression drugs market in Asia Pacific is anticipated to expand at a higher CAGR compared to that in other regions from 2020 to 2030. Growth of the depression drugs market in Asia Pacific can be ascribed to rise in prevalence of depression disorders and increase in awareness about the treatment of depression in the region.

Competition Landscape

The global depression drugs market is fragmented in terms of number of players. Key players operating in the global depression drugs market include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Allergan, Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott, Pfizer, and GlaxoSmithKline. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players in the global depression drugs market.

Browse More Trending Reports by Transparency Market Research:

Heparin Market: According to Transparency Market Research’s latest report on the global heparin market for the historical period 2017–2018 and forecast period 2019–2027, high incidence and mortality associated with coagulation disorders, commercialization of safe and cost-effective heparin products are projected to drive the global heparin market during the forecast period.

North America Blood Collection Tubes Market: Rise in demand for diagnostic procedures is a key trend bolstering the demand for blood collection tubes. Prevalence of chronic diseases in various countries has spurred the use of blood collection tubes by clinicians.

Macular Degeneration Treatment Market: Macular degeneration treatment breakthroughs inspire hope that someday we may see a cure to this disease.  Promising treatments, described below, depend upon the stage of disease progression. The treatment for early dry macular degeneration is generally nutritional therapy, with a healthy diet high in antioxidants to support the cells of the macula.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/